Flutamide_NN
in_IN
the_DT
treatment_NN
of_IN
hirsutism_NN
:_:
long-term_JJ
clinical_JJ
effects_NNS
,_,
endocrine_JJ
changes_NNS
,_,
and_CC
androgen_NN
receptor_NN
behavior_NN
._.

OBJECTIVE_NN
:_:
To_TO
investigate_VB
the_DT
long-term_JJ
effects_NNS
of_IN
treatment_NN
with_IN
low_JJ
doses_NNS
of_IN
flutamide_NN
on_IN
clinical_JJ
and_CC
hormonal_JJ
parameters_NNS
,_,
as_RB
well_RB
as_IN
on_IN
the_DT
androgen_NN
receptor_NN
status_NN
,_,
in_IN
hirsute_JJ
women_NNS
._.

DESIGN_NN
:_:
Eighteen_CD
hirsute_JJ
patients_NNS
with_IN
regular_JJ
menses_NNS
were_VBD
studied_VBN
basally_RB
and_CC
during_IN
treatment_NN
with_IN
125_CD
mg_NN
flutamide_NN
,_,
three_CD
times_NNS
per_IN
day_NN
for_IN
12_CD
months_NNS
._.

Barrier_NN
or_CC
intrauterine_JJ
contraception_NN
was_VBD
used_VBN
during_IN
the_DT
study_NN
in_IN
sexually_RB
active_JJ
women_NNS
._.

Safety_NN
parameters_NNS
were_VBD
assessed_VBN
throughout_IN
the_DT
study_NN
._.

Hirsutism_NN
,_,
graded_VBN
by_IN
the_DT
modified_VBN
Ferriman-Gallwey_JJ
score_NN
,_,
and_CC
hormonal_JJ
parameters_NNS
were_VBD
evaluated_VBN
basally_RB
and_CC
at_IN
4-month_JJ
intervals_NNS
during_IN
treatment_NN
._.

Gonadotropin-releasing_JJ
hormone_NN
and_CC
ACTH_NN
stimulation_NN
tests_NNS
were_VBD
performed_VBN
before_IN
and_CC
after_IN
3_CD
to_TO
4_CD
months_NNS
of_IN
therapy_NN
._.

In_IN
addition_NN
,_,
the_DT
concentration_NN
of_IN
androgen_NN
receptors_NNS
in_IN
mononuclear_JJ
leukocytes_NNS
was_VBD
measured_VBN
,_,
in_IN
both_CC
the_DT
follicular_JJ
and_CC
luteal_JJ
phases_NNS
of_IN
the_DT
menstrual_JJ
cycle_NN
,_,
basally_RB
and_CC
after_IN
4_CD
months_NNS
of_IN
flutamide_NN
treatment_NN
._.

RESULTS_NNS
:_:
Flutamide_NN
was_VBD
well_RB
tolerated_VBN
in_IN
all_DT
women_NNS
,_,
with_IN
the_DT
noticeable_JJ
exception_NN
of_IN
one_CD
patient_NN
who_WP
presented_VBD
increased_VBN
serum_NN
transaminase_NN
after_IN
8_CD
months_NNS
of_IN
therapy_NN
._.

Hirsutism_NN
markedly_RB
improved_VBD
in_IN
all_DT
women_NNS
during_IN
the_DT
treatment_NN
-LRB-_-LRB-
Ferriman-Gallwey_JJ
score_NN
after_IN
1_CD
year_NN
:_:
4.1_CD
+_CC
\/_NN
-_:
0.5_CD
versus_CC
14.1_CD
+_CC
\/_NNP
-_:
0.9_CD
-RRB-_-RRB-
._.

A_DT
reduction_NN
of_IN
serum_NN
androgens_NNS
was_VBD
found_VBN
,_,
whereas_IN
no_DT
change_NN
was_VBD
observed_VBN
in_IN
either_CC
basal_JJ
or_CC
GnRH-stimulated_JJ
gonadotropins_NNS
or_CC
in_IN
the_DT
cortisol_NN
and_CC
17_CD
alpha-hydroxyprogesterone_NN
response_NN
to_TO
ACTH_NN
._.

Cycles_NNS
remained_VBD
ovulatory_JJ
._.

Before_IN
treatment_NN
,_,
the_DT
number_NN
of_IN
androgen_NN
receptors_NNS
was_VBD
higher_JJR
in_IN
the_DT
luteal_NN
than_IN
in_IN
the_DT
follicular_JJ
phase_NN
._.

This_DT
rhythmic_JJ
differentiation_NN
disappeared_VBD
after_IN
the_DT
patients_NNS
had_VBD
been_VBN
given_VBN
the_DT
antiandrogen_JJ
drug_NN
._.

CONCLUSIONS_NNS
:_:
Flutamide_NN
is_VBZ
effective_JJ
in_IN
the_DT
treatment_NN
of_IN
hirsutism_NN
but_CC
requires_VBZ
constant_NN
surveillance_NN
of_IN
liver_NN
function_NN
._.

Androgen_NN
receptor_NN
blockade_NN
might_MD
be_VB
potentiated_VBN
by_IN
a_DT
reduction_NN
of_IN
serum_NN
androgens_NNS
._.

Flutamide_NN
affects_VBZ
androgen_NN
receptor_NN
behavior_NN
during_IN
the_DT
menstrual_JJ
cycle_NN
._.

The_DT
meaning_NN
of_IN
this_DT
finding_NN
remains_VBZ
to_TO
be_VB
elucidated_VBN
._.

